Find Academic Supervisors

• Breast cancer
• Translational oncology
• Circulating tumour cells
• +6 more

Alexios Matikas, MD, PhD , is Associate Professor of Oncology at Karolinska Institutet and Senior Consultant in Medical Oncology at the Karolinska Comprehensive Cancer Center Breast Center. Appointed Docent in May 2021, he leads translational breast-cancer research within the Theodoros Foukakis Group at the Department of Oncology-Pathology. Since 2024 he also serves as Deputy Director of Doctoral Education at the department and sits on Karolinska Institutet’s central Dissertation Committee. Education & Training MD, Aristotle University Medical School, Greece (with scholarship for academic excellence) MSc Cancer Cell Biology, Athens Medical School (valedictorian) PhD, Circulating Tumour Cells, Crete Medical School ESMO Georges Mathé Fellowship in Immuno-Oncology, Karolinska Institutet (2016–2017) Post-doc in breast-cancer immunology, Karolinska Institutet (2017–) Research Focus Matikas’ work integrates clinical trials, real-world evidence and high-resolution multi-omics to dissect the tumour-host interface in breast cancer. He is principal investigator of the international academic ARIADNE trial (NCT05900206) exploring biology-driven neoadjuvant HER2-targeted therapy, and leads registry-based studies using Swedish national databases to answer clinically relevant questions. His laboratory interrogates spatial and temporal tumour-immune dynamics using digital pathology, single-cell sequencing and proteomics to identify predictive biomarkers and therapeutic vulnerabilities. Scientific Awards & Honours ESMO Georges Mathé Fellowship in Immuno-Oncology (2016–2017) Percy Falk stipend for breast and prostate cancer research Aristotle University scholarship for academic excellence Teaching & Mentorship He is main supervisor for three and co-supervisor for five PhD candidates across Karolinska Institutet and Sahlgrenska Academy. He has accrued 260 hours of formal teaching at KI and co-created the doctoral course “Basic principles of clinical and translational research”. Together with international experts he founded the Academy of Breast Oncology , a webinar series for young oncologists (2020–2025, 13 sessions). Leadership & Service Within ESMO he previously sat on the Young Oncologists Committee (2020–2023) and now contributes to the Leadership Development Committee, OncologyPRO working group and Magnitude of Clinical Benefit Scale working group. Nationally, he coordinates adjuvant therapy guidelines for the Swedish National Breast Cancer Guidelines and serves on the Stockholm regional treatment guidelines committee.

Mingyao LiView profile

Associate Professor

• Bioinformatics
• Biostatistics
• Genetics
• +2 more

Mingyao Li, PhD, is an Associate Professor of Biostatistics whose scholarship bridges high-dimensional statistics with modern genomics and spatial biology. Her work is recognised for advancing computational methods that dissect complex tissue architecture and disease heterogeneity at single-cell resolution. Research Interests Bioinformatics and computational biology Statistical methods for high-dimensional genomic data Single-cell and spatial multi-omics integration Genetics and genomics of cardiovascular and cancer systems Systems biology approaches to disease mechanisms Across more than one hundred peer-reviewed publications, Li’s research exhibits a clear trajectory from developing rigorous statistical frameworks—such as hypothesis testing in stochastic block models—to large-scale applications in human disease. A dominant theme is the fusion of spatial transcriptomics, single-cell multi-omics and AI-driven image analysis to uncover cell-type heterogeneity, lineage relationships and microenvironmental crosstalk in atherosclerosis, lung adenocarcinoma, pancreatic cancer and neurodegenerative disorders. Scientific Awards & Recognition While specific awards are not listed in the provided text, the consistent appearance of Dr Li as senior or corresponding author on high-impact papers in Nature family journals and the development of widely-used computational tools (e.g., MISO, iSCALE) attest to significant scholarly recognition. Research Support & Teams Granting agencies and collaborative networks are not explicitly detailed, but the scale and scope of the projects—from whole-organ spatial atlases to primate genome-editing studies—imply substantial multi-institutional funding and interdisciplinary teams integrating biostatisticians, wet-lab scientists and clinician-scientists.

Madhvi MenonView profile

Research Fellow

• Immunology
• Respiratory Diseases
• Autoimmunity
• +2 more

Dr. Madhvi Menon is a UKRI Future Leaders Fellow at the University of Manchester, affiliated with the Division of Immunology, Immunity to Infection and Respiratory Medicine. Her research focuses on B cell interactions in chronic respiratory diseases and autoimmunity, with a specific emphasis on COPD, autoantibody mechanisms, and interferon signaling pathways. Education: PhD in Immunology from University College London (2015) Postdoctoral Training: Harvard Medical School (age-related macular degeneration research), University College London (rheumatoid arthritis pathogenesis) Research trends include inflammatory pathway analysis in autoimmune disorders, miRNA/cytokine profiling in viral infections, and monocyte migration dynamics in acute/long COVID-19. Key subfields span autoantibody functionality, interferon isoform interactions, and spatially-resolved omics applications. Scientific Award: UKRI Future Leaders Fellowship Currently supervises three PhD students (Holly Sedgwick, Maana Layeghi, Rebecca Rowan) and collaborates on multi-institutional projects like 'Laser capture dissection for spatially-resolved -omics analysis.'

Suming HuangView profile

Professor

• Epigenetics
• Gene Regulation
• Leukemia Research
• +5 more

Suming Huang serves as Professor and Chair of the Four Diamonds Epigenetics and Gene Regulation Research Program in Pediatric Oncology at Penn State University's College of Medicine. Holding dual appointments in the Department of Pediatrics Division of Hematology and Oncology and the Department of Molecular and Precision Medicine, Huang directs research within the Penn State Cancer Institute's Mechanisms of Carcinogenesis program. With an h-index of 36 and over 4,000 citations, Huang maintains an active research profile through the National Cancer Institute. Huang's research centers on epigenetic mechanisms in leukemia development, specializing in transcriptional regulation, non-coding RNA functions, and chromatin organization. Key focus areas include TAL1/SCL regulation in T-cell leukemia, lncRNA-mediated genome organization in AML, and the role of histone modifiers like HDAC1 in tumor suppression. The research integrates hematopoietic stem cell biology with leukemogenesis pathways, particularly examining how non-coding RNAs reprogram chromatin architecture in NUP98-rearranged leukemias and other hematological malignancies. Current publication trends reveal consistent output in high-impact oncology journals, with 2025 publications examining CK2α deletion effects on stem cells, IKAROS/HDAC1 heterochromatin regulation, guanine biosynthesis blockade in MLL leukemias, and HoxBlinc lncRNA functions. These works demonstrate Huang's shift toward therapeutic targeting of epigenetic vulnerabilities while maintaining core investigations into transcriptional dysregulation in pediatric cancers. Huang leads eight major research projects including the active National Cancer Institute grant Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization (2021-2025). Past projects span leukemogenesis mechanisms, long non-coding RNA functions in hematopoiesis, and TAL1 regulation in T-cell leukemia, securing sustained NCI funding since 2008. The research program maintains strong collaborations across hematology-oncology and molecular medicine departments. The Four Diamonds Epigenetics and Gene Regulation Research Program in Pediatric Oncology serves as Huang's primary research hub, focusing on translating epigenetic discoveries into therapeutic strategies for childhood leukemias. Current work integrates multi-omics approaches to dissect lncRNA-mediated chromatin reorganization in leukemic stem cells.

• Chemical Biology
• Cancer Research
• Metal Biology
• +6 more

Raphaël Rodriguez serves as CNRS Research Director, Team Leader of the Biomedicine group, and Deputy Director of the Chemical Biology of Cancer research unit (U1339/UMR3666) at Institut Curie in Paris. His interdisciplinary work bridges synthetic chemistry and molecular biology to investigate metal ion-driven cellular processes. His research focuses on metal-mediated cell adaptation in cancer and inflammation, revealing CD44's role in copper/iron uptake that regulates epigenetic programming and metabolic rewiring. Key innovations include identifying lysosomal iron as a ferroptosis trigger and developing first-in-class small molecules targeting metal-dependent pathways for therapy-resistant cancers. Recent publications demonstrate consistent leadership in Metal ion trafficking in disease states Ferroptosis modulation for cancer therapy Chemical intervention in inflammation/ageing with major contributions to understanding copper's role in NAD(H) redox cycling and iron's transcriptional regulation. Award highlights: CNRS Silver Medal (2024) Liliane Bettencourt Prize (2023) Klaus Grohe Prize for drug development (2022) Tetrahedron Young Investigator Award As Deputy Director of Research Unit, Rodriguez leads grant-funded projects developing chemical probes for cell adaptation mechanisms. His team's work on remodelin, ironomycin, and salinomycin has spawned multiple biotech ventures. Current efforts focus on translating metal-targeting molecules into clinical applications for therapy-resistant cancers and inflammatory disorders through Institut Curie's innovation ecosystem. The Biomedicine team operates within Institut Curie's Chemical Biology of Cancer unit, utilizing integrated chemical biology platforms including click chemistry-based fluorescent tagging, multi-omics analysis, and organic synthesis facilities to dissect metal-dependent pathways in melanoma, pancreatic cancer, and acute kidney injury models.

Hussein Al-MossawiView profile

Academic

• Rheumatology
• Translational Immunology
• Autoimmune Inflammatory Diseases
• +6 more

Dr Hussein Al-Mossawi is an NIHR Academic Clinical Lecturer in Rheumatology at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, and concurrently a Fellow by Special Election in Medical Sciences and lecturer in pathology & immunology at St Edmund Hall, University of Oxford. He also lectures at Exeter College. Education 2006 – BMBCh (Medicine), Trinity College, University of Oxford 2016 – DPhil (Translational Immunology), University of Oxford 2016 – MA, University of Oxford MRCP (Rheumatology), Royal College of Physicians Research Focus Dr Al-Mossawi’s research centres on dissecting immune responses in autoimmune inflammatory diseases, with a particular emphasis on psoriatic arthritis and spondyloarthritis. Using cutting-edge single-cell multi-omics, flow cytometry and patient-derived clinical trials, his group investigates: GM-CSF biology and its role in axial & peripheral spondyloarthritis IL-7R polymorphisms and inflammatory signalling Immunological mechanisms underpinning psoriatic arthritis Biomarker discovery for stratified therapy Scientific Awards Wellcome Trust Clinical Fellowship (2012–2016) Research Leadership & Funding Dr Al-Mossawi currently leads translational projects funded by the NIHR and Wellcome Trust, including the phase 2 NAMASTE trial targeting GM-CSF in axial spondyloarthritis and the Oxford Psoriatic Arthritis Centre (Ox-PACE) programme. He mentors early-career clinician-scientists and contributes to undergraduate teaching in pathology and immunology across multiple Oxford colleges. Laboratory & Teams He works within the Oxford Psoriatic Arthritis Centre (Ox-PACE) and collaborates closely with the Powrie and Bowness groups at the Kennedy Institute of Rheumatology and the Translational Gastroenterology Unit, fostering interdisciplinary projects that span rheumatology, hepatology and mucosal immunology.

Vilde Olsson LalunView profile

Research Fellow

• Plant Molecular Biology
• Genetics
• Evolutionary Biology
• +7 more

Vilde Olsson Lalun is a postdoctoral fellow at the Centre for Ecological and Evolutionary Synthesis (CEES), University of Oslo. She obtained her BSc and MSc in Molecular Biology at UiO in 2013 and 2015, respectively, and completed her PhD in Genetics in 2020 under the supervision of Prof. Melinka Alonso Butenko. Her current research integrates experimental biology and bioinformatics within the interdisciplinary REPEAT project, focusing on how short tandem repeat (STR) variation influences adaptation and gene expression in Arabidopsis thaliana and Atlantic cod. Education 2013 – BSc in Molecular Biology, University of Oslo 2015 – MSc in Molecular Biology (Plant Genetics), University of Oslo 2020 – PhD in Genetics, Department of Biosciences, University of Oslo Thesis: "Molecular investigation of receptor kinase signaling specificity in Arabidopsis thaliana" Research Interests Dr Lalun’s work sits at the intersection of molecular plant biology , evolutionary genomics , and functional genetics . During her PhD she dissected peptide ligand–receptor kinase specificity using the IDA–HAE/HSL2 signalling module as a model. Presently, she investigates how STR length polymorphisms modulate gene expression and organismal fitness under environmental stress, leveraging both Arabidopsis and Atlantic cod as complementary model systems. Core methodological strengths include generation of transgenic lines, advanced live-cell imaging, quantitative microscopy, and integrative bioinformatic analyses. She actively contributes to the REPEAT consortium, an interdisciplinary team that addresses fundamental questions of genome plasticity and climate adaptation. By coupling large-scale comparative genomics with targeted experiments, the project aims to clarify how repetitive DNA elements shape regulatory networks controlling development and immunity. Publication Profile Across 11 peer-reviewed papers (2017-2025) in high-impact journals such as Nature Communications , PNAS , eLife , and Plant Cell , her research spans three major themes: Functional dissection of peptide signalling pathways in plant development and immunity. Comparative genomics of short tandem repeats and their impact on gene regulation. Mechanistic studies of receptor kinase activation and signalling specificity. The 2024-2025 outputs include a lead-author review on plant peptide ligands and multi-omics studies that link STR variation to gene body architecture in eukaryotes. Teaching & Outreach Dr Lalun is a committed educator and science communicator. She instructs two undergraduate courses: BIOS1120 – Physiology BIOS3610 – Molecular Plant Science Beyond the classroom she co-hosts the Norwegian-language podcast BioPodden , produces popular-science YouTube lectures, and gives interviews that demystify plant genetics for the public. Collaborations & Networks She is an active member of the Butenko Group at UiO and collaborates extensively within the CEES and the national REPEAT project network. The lab provides cutting-edge facilities for molecular biology, microscopy and bioinformatics, ensuring a vibrant environment for integrative research.

• Mitochondrial fatty-acid β-oxidation
• Post-translational redox modifications
• Nitric-oxide signalling
• +6 more

Paschalis-Thomas Doulias is Associate Professor of Organic Chemistry and Biochemistry in the Department of Chemistry at the University of Ioannina, Greece. His laboratory, located in Ioannina Campus building X3-106D, investigates the molecular mechanisms governing mitochondrial fatty-acid β-oxidation and their translational exploitation for rare inherited disorders of long-chain fatty-acid oxidation. Research Interests His research spans two tightly integrated themes: Basic Research: Elucidating post-translational redox modifications—particularly S-nitrosylation, acetylation and succinylation—that regulate key enzymes of mitochondrial fatty-acid oxidation. Work uses genetically modified mouse models (Sirt-3 -/- , Sirt-5 -/- , eNOS -/- and VLCAD Cys238Ala knock-in) complemented by cellular mutagenesis to dissect how energetic demand is coupled to enzymatic flux. Translational Research: Developing nitric-oxide-based therapies for long-chain fatty-acid oxidation disorders (LC-FAODs). The group pioneered the concept that augmenting NO signalling restores catalytic efficiency of mutant VLCAD, and is currently validating FDA-approved NO donors and proprietary hybrid NO-plus-substrate molecules in patient-derived cells and a humanised VLCAD-deficient mouse. Publication Landscape (2020-2025) Over the past five years, Doulias and collaborators have generated 15 high-impact articles that collectively map redox-proteomic landscapes in cardiovascular, neurodegenerative and metabolic disease contexts. Recurring keywords include S-nitrosylation, TCA-cycle compromise, mitochondrial energetics, HFpEF, ALS and Alzheimer’s disease, underscoring a unifying theme of redox-metabolic crosstalk. Scientific Awards & Recognition While specific honours are not enumerated, the consistent citation of his work (H-index 30, 3571 citations) attests to significant peer recognition. Funding & Collaborations Active translational projects include medicinal-chemistry optimisation of NO-donating compounds and in vivo efficacy testing in humanised mouse models of VLCAD deficiency, implying sustained competitive funding and multi-disciplinary partnerships. Laboratory & Team The group operates within the Department of Chemistry core facilities, leveraging state-of-the-art proteomics, metabolomics and transgenic animal resources to advance both basic and pre-clinical goals.

• Molecular Biology
• Transcriptomics
• HPV-Related Cancers
• +3 more

Dr. Hiroko Matsunaga is a Senior Researcher (Research Associate Professor) at Waseda University's Research Organization for Nano & Life Innovation since 2025. She previously held positions at Waseda University (1993-2018), Central Research Laboratory at Hitachi, Ltd. (1993-2018), and was a Visiting Scholar at Iowa State University (2001-2003) and Aika State University (1994-1995). She earned her Doctor of Science from Osaka Prefecture University in 1993. Education: PhD (Science) from Osaka Prefecture University (1989-1993) Her research focuses on molecular biology, particularly in single-cell and microtissue transcriptomics, HPV18-related cervical cancers, and spatial gene expression analysis in diseases like Alzheimer's and Marfan syndrome. She has pioneered methods for spatial transcriptomics using FFPE tissues and developed tools for precision medicine in rare cancers. Recent publications highlight her work in spatial transcriptomics, HPV18 infection mechanisms, and applications of organoid models. Her methodologies integrate advanced biotechnology with bioinformatics to address tumor heterogeneity, viral carcinogenesis, and cardiovascular pathologies. She contributes to grants like the JSPS-funded project on personalized lung cancer medicine. She has co-authored patents in nucleic acid analysis, cell collection systems, and gene detection methods. Collaborations span institutions like Osaka University, Iowa State University, and Aika State University.

• Computational Biology
• Immunology
• Genetics
• +3 more

Ghaith ABDESSALEM is a postdoctoral fellow in computational biology at the IMAGINE Institute, University of Paris, working in the 'Inflammatory Responses and Transcriptomic Networks in Diseases' Laboratory since May 2018. His research focuses on rare inflammatory disorders using single-cell multi-omics technologies including scRNAseq, scCITEseq, and scATACseq with 10X Genomics platforms. Education: Master's degree in Fundamental and Applied Immunology Doctoral research at the Laboratory of Biomedical Genomics and Oncogenetics, Pasteur Institute in Tunis His expertise bridges genetic, immunological, and computational domains to investigate rare inherited inflammatory diseases. Specializing in Next Generation Sequencing data analysis (exome, genome, microarray), he developed human exome/genome sequencing pipelines accredited through the H3Africa network. Current work examines rare hereditary skin disorders in North African populations and molecular signatures of SARS-CoV-2-related inflammatory syndromes using cutting-edge single-cell multi-omics approaches. His 2020-2021 publications reveal consistent focus on transcriptional networks in immune cells and bone biology, demonstrating advanced applications of multi-omic integration to dissect disease mechanisms in inflammatory disorders and skeletal development. Research spans from fundamental osteoblast regulation to clinical manifestations of viral-triggered hyperinflammation. He operates within the 'Inflammatory Responses and Transcriptomic Networks in Diseases' Laboratory, which employs high-throughput single-cell technologies to decode molecular pathways in rare inflammatory conditions through computational biology frameworks.

Joanna JankowskyView profile

Professor

• Alzheimer's Disease
• Neuroscience
• Neurodegenerative Diseases
• +4 more

Joanna Jankowsky serves as Professor of Neuroscience and Theodore and Bertha Bryan Professor of Environmental Medicine at Washington University School of Medicine, leading research on Alzheimer's disease pathogenesis through genetically engineered mouse models. Her work investigates genetic, environmental, and aging factors influencing dementia risk and progression. Her educational background includes: PhD in Cellular and Molecular Neuroscience, California Institute of Technology (1993-1999) BA in Biology, Amherst College (1987-1991) Dr. Jankowsky's research centers on Alzheimer's disease mechanisms , with emphasis on TMEM106B genetics , disease heterogeneity , and amyloid-targeting interventions . Her lab develops transgenic models to dissect neural circuit vulnerability and protein aggregation dynamics, exploring how genetic variants influence resilience to tauopathy and amyloid pathology. Recent publications (2021-2024) reveal consistent focus on Alzheimer's mechanisms using transgenic models, with key themes including TMEM106B's protective role in tauopathy, activity-dependent neurodegeneration in memory circuits, and innovative Aβ-targeting gene therapies. These works bridge neuroscience, molecular genetics, and therapeutic development. Her scientific recognition includes: Vivian L. Smith Endowed Chair in Neuroscience (Baylor College of Medicine, 2020-2025) Alzheimer’s Association Zenith Fellows Award (2019-2022) NIH Director’s New Innovator Award (DP2, 2007-2012) NIH Mentored Research Scientist Award (K01, 2004-2009) NARSAD Young Investigator Award (2004-2006) Dr. Jankowsky mentors trainees through the Jankowsky Lab while securing major grants including NIH New Innovator and Zenith Fellow awards. Her collaborative work spans neuroscience departments and leverages viral vector technologies for therapeutic development. The Jankowsky Lab maintains three core research thrusts: TMEM106B isoform effects on dementia risk using multi-omics approaches, structural determinants of protein aggregate toxicity, and amyloid-targeting gene therapies delivered via neuroscience-derived viral tools. The lab actively distributes its mouse models to accelerate global Alzheimer's research.

• Medical Biotechnology
• Biochemistry
• Cell Biology
• +6 more

Pirkko Mattila serves as Research Director and Senior Researcher at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, holding a joint appointment with the Finnish Red Cross Blood Service since 2014. She supervises the Doctoral Programme in Biomedicine and has maintained continuous research activity for over 35 years through roles at Haartman Institute and industry. Her academic credentials include: Docent (2011) PhD (1993) Master of Science in Biochemistry (1989) Dr. Mattila's research integrates medical biotechnology with molecular pathology, focusing on cellular stress responses in genetic disorders, oxidative stress mechanisms in age-related macular degeneration, and neutrophil inflammasome dynamics during viral infections. She pioneers single-cell analytics to dissect disease heterogeneity, with recent work establishing quality frameworks for multi-omics in personalized medicine through European infrastructure projects. Her publication trajectory shows increasing translational focus since 2015, with 2024-2025 outputs spanning high-impact journals in omics methodology (Nature Biotechnology), ophthalmology (IOVS), and immunology (PLoS Pathogens). This reflects strategic alignment with EU initiatives like EATRIS-Plus for clinical implementation. Dr. Mattila actively mentors doctoral candidates through structured supervision in the Biomedicine Programme. Her current research is sustained by two major grants: EU-OPENSCREEN ERIC Suomi FIRI (Academy of Finland, 2025-2027) as Project Manager Airway disease pathogenesis project (since 2011) as core participant She directs the FIMM Single-Cell Analytics facility, a national infrastructure providing cutting-edge omics services to academic and clinical partners across the Nordic region. The lab emphasizes quality-controlled workflows and cross-validation with histopathology, supporting her vision of precision medicine grounded in molecular evidence.

Emma Sofie Timm AllerView profile

Research Fellow

• Plant Stress Response
• Epigenetics
• Bioinformatics
• +2 more

Emma Sofie Timm Aller is a Postdoc at the Department of Plant and Environmental Sciences, Section for Molecular Plant Biology, within the Faculty of Science at the University of Copenhagen. She is affiliated with the DynaMo Center for dynamic molecular interactions, where she investigates plant-environment interactions through molecular and epigenetic lenses. Her academic credentials include: MSc in Biology-Biotechnology from the University of Copenhagen (2013-2015) BSc in Biology-Biotechnology from the University of Copenhagen (2009-2013) Dr. Aller's research examines how plants develop phenotypic variation to cope with environmental stress through non-genetic mechanisms, with particular focus on stress signal communication across plant generations. She employs advanced bioinformatic techniques to analyze sequencing data and map molecular networks affected by stressors. Her work bridges computational biology with experimental plant science to address climate resilience challenges. Publication analysis reveals consistent emphasis on epigenetic regulation of plant plasticity, with recent work expanding from foundational trait stability studies (2018) to comprehensive transgenerational inheritance frameworks (2022). The research trajectory demonstrates increasing integration of multi-omics approaches to dissect stress response pathways. As an active member of the DynaMo Center, she collaborates within interdisciplinary teams studying dynamic molecular interactions in plant systems. Her current work continues to explore epigenetic memory mechanisms while investigating stress signal transmission between neighboring plants.

• Twin Genetics
• Nature versus Nurture
• Genetics of complex disease
• +2 more

Erik Ehli serves as Medical Associate Professor in Biomedical & Translational Sciences and Assistant Professor in Psychiatry at the University of South Dakota's Sanford School of Medicine. His research bridges clinical psychiatry with genetic epidemiology, specializing in twin studies to dissect nature-nurture interactions in complex diseases. Education: Ph D, Basic Biomedical Sciences, University of South Dakota, 2013 BS, Nursing, South Dakota State University, 2005 MS, Basic Biomedical Sciences, University of South Dakota, 2004 BS, Biology, Northern State University, 1998 Dr. Ehli's research program centers on twin genetics to quantify hereditary versus environmental contributions across multiple domains. His work spans cancer genetics (investigating familial aggregation), pharmacogenetics (drug response variability), and complex disease genetics (integrating multi-omics approaches). The Nature versus Nurture framework underpins all investigations, utilizing twin cohorts to isolate genetic effects from environmental confounders in psychiatric and metabolic conditions. Recent publications demonstrate methodological diversity: genomic sequencing of medicinal leech models (2020), neurobehavioral phenotyping in alcohol-affected populations (2018), and translational phytochemical trials (2012). This portfolio reveals consistent focus on gene-environment interplay across species and experimental paradigms, with increasing emphasis on molecular mechanisms underlying psychiatric and metabolic disorders.

• Neuroimmunology
• Neurodegenerative Diseases
• Single-cell Omics
• +4 more

Marc Beyer serves as Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, holding the academic rank of Associate Professor. His research investigates bidirectional immune-brain interactions during aging and neurodegeneration, with emphasis on T cell and microglial mechanisms in Alzheimer's, Parkinson's, and post-COVID neurological complications. Dr. Beyer's group pioneers single-cell multi-omic approaches including snRNA-seq, scATAC-seq, and spatial transcriptomics to decode cellular heterogeneity in neurodegenerative contexts. Key projects involve creating human brain cell atlases (DFG-NGS collaboration), characterizing dopaminergic neuron transcriptional changes in Parkinson's, and exploring 'innate immune memory' in microglia. The NeuroCOV initiative identifies peripheral blood immune signatures linked to long-term cognitive decline after SARS-CoV-2 infection. Scientific Awards: No awards specified in source materials. Dr. Beyer directs multiple high-impact projects including a large DZNE cohort study on peripheral immunity in early dementia and the European NeuroCOV consortium. These initiatives employ high-throughput single-cell analysis of PBMCs to develop biomarkers for early therapeutic intervention, though specific grant details and student mentorship records remain unlisted. The research team operates from DZNE's Venusberg Campus facility, utilizing CRISPR-Cas9 lineage tracing (LINC mouse model), high-dimensional flow cytometry, and multimodal omics platforms to dissect neuroimmune crosstalk in physiological and pathological CNS states.